Metabolic diseases, including obesity, diabetes, and cardiovascular disorders, are increasingly prevalent due to genetic, environmental, and lifestyle factors. Sterol regulatory element-binding proteins (SREBPs) are key transcription factors that regulate genes involved in lipid synthesis and cholesterol homeostasis. Dysregulation of SREBPs contributes to metabolic disorders, with overactivation of SREBP-1c driving excessive lipid synthesis, leading to hyperlipidemia. In diabetes, altered SREBP activity impairs insulin secretion and promotes lipid accumulation, exacerbating disease progression. SREBP-2 is critical for cholesterol metabolism and is linked to atherosclerosis. This review explores the therapeutic potential of targeting SREBPs. Compounds such as betulin, fatostatin, xanthohumol, vitamin D derivatives, and BF175 can modulate SREBP activity, reduce lipid accumulation, and improve metabolic outcomes in experimental models. Clarifying SREBP regulatory mechanisms across tissues, advancing small-molecule modulators, and applying gene-editing technologies such as CRISPR-Cas9 may enable more personalized therapeutic strategies. Integrating lifestyle interventions with pharmacological treatments may offer a comprehensive approach to improving therapeutic outcomes in metabolic diseases.
HoffmanDJ, PowellTL, BarrettES, et al.Developmental origins of metabolic diseases. Physiol Rev, 2021; 101(3):739–795; doi: 10.1152/physrev.00002.2020
2.
Clemente-SuárezVJ, Beltrán-VelascoAI, Redondo-FlórezL, et al.Global impacts of western diet and its effects on metabolism and health: A narrative review. Nutrients, 2023; 15(12):2749; doi: 10.3390/nu15122749
3.
KassiE, KyrouI, RandevaHS. Atherosclerotic and cardio-metabolic diseases: From molecular basis to therapeutic advances. Int J Mol Sci, 2023; 24(11):9737; doi: 10.3390/ijms24119737
WangM, KaufmanRJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature, 2016; 529(7586):326–335; doi: 10.1038/nature17041
6.
ShenS, ShenM, KuangL, et al.SIRT1/SREBPs-mediated regulation of lipid metabolism. Pharmacol Res, 2024; 199:107037; doi: 10.1016/j.phrs.2023.107037
7.
XiongY, LuoJ, HongZY, et al.Hyperactivation of SREBP induces pannexin-1-dependent lytic cell death. J Lipid Res, 2024; 65(7):100579; doi: 10.1016/j.jlr.2024.100579
8.
YanR, CaoP, SongW, et al.Structural basis for sterol sensing by Scap and Insig. Cell Rep, 2021; 35(13):109299; doi: 10.1016/j.celrep.2021.109299
9.
JeonTI, OsborneTF. SREBPs: Metabolic integrators in physiology and metabolism. Trends Endocrinol Metab, 2012; 23(2):65–72; doi: 10.1016/j.tem.2011.10.004
10.
BolshetteN, EzagouriS, DandavateV, et al.Carbon dioxide regulates cholesterol levels through SREBP2. PLoS Biol, 2023; 21(11):e3002367; doi: 10.1371/journal.pbio.3002367
11.
DuanY, GongK, XuS, et al.Regulation of cholesterol homeostasis in health and diseases: From mechanisms to targeted therapeutics. Signal Transduct Target Ther, 2022; 7(1):265; doi: 10.1038/s41392-022-01125-5
12.
MaoZ, ZhangW. Role of mTOR in glucose and lipid metabolism. Int J Mol Sci, 2018; 19(7):2043; doi: 10.3390/ijms19072043
13.
RenY, ShenHM. Critical role of AMPK in redox regulation under glucose starvation. Redox Biol, 2019; 25:101154; doi: 10.1016/j.redox.2019.101154
14.
PetersenMC, ShulmanGI. Mechanisms of insulin action and insulin resistance. Physiol Rev, 2018; 98(4):2133–2223; doi: 10.1152/physrev.00063.2017
15.
BhatN, ManiA. Dysregulation of lipid and glucose metabolism in nonalcoholic fatty liver disease. Nutrients, 2023; 15(10):2323; doi: 10.3390/nu15102323
16.
Ozkan-NikitarasT, GrzesikDJ, RomanoL, et al.N-SREBP2 provides a mechanism for dynamic control of cellular cholesterol homeostasis. Cells, 2024; 13(15):1255; doi: 10.3390/cells13151255
17.
DuanJ, HuangZ, NiceEC, et al.Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res, 2023; 48:105–123; doi: 10.1016/j.jare.2022.08.007
18.
BaiXP, DongF, YangGH, et al.Influences of sterol regulatory element binding protein-1c silencing on glucose production in HepG2 cells treated with free fatty acid. Lipids Health Dis, 2019; 18(1):89; doi: 10.1186/s12944-019-1026-3
19.
FengX, ZhangR, YangZ, et al.Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism. J Clin Transl Hepatol, 2024; 12(9):815–826; doi: 10.14218/JCTH.2024.00019
20.
WuYR, LiL, SunXC, et al.Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells. Nutr Metab Cardiovasc Dis, 2021; 31(1):322–332; doi: 10.1016/j.numecd.2020.08.012
21.
LiQ, YaoH, WangY, et al.circPRKAA1 activates a Ku80/Ku70/SREBP-1 axis driving de novo fatty acid synthesis in cancer cells. Cell Rep, 2022; 41(8):111707; doi: 10.1016/j.celrep.2022.111707
22.
ChengC, GengF, LiZ, et al.Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth. Nat Metab, 2022; 4(5):575–588; doi: 10.1038/s42255-022-00568-y
23.
Gluba-SagrA, FranczykB, Rysz-GórzyńskaA, et al.The role of selected lncRNAs in lipid metabolism and cardiovascular disease risk. Int J Mol Sci, 2024; 25(17):9244; doi: 10.3390/ijms25179244
24.
LiN, LiM, HongW, et al.Brg1 regulates pro-lipogenic transcription by modulating SREBP activity in hepatocytes. Biochim Biophys Acta Mol Basis Dis, 2018; 1864(9 Pt B):2881–2889; doi: 10.1016/j.bbadis.2018.05.022
25.
Bravo-RuizI, MedinaMÁ, Martínez-PovedaB. From food to genes: Transcriptional regulation of metabolism by lipids and carbohydrates. Nutrients, 2021; 13(5):1513; doi: 10.3390/nu13051513
26.
LeeSH, ParkSY, ChoiCS. Insulin resistance: From mechanisms to therapeutic strategies. Diabetes Metab J, 2022; 46(1):15–37; doi: 10.4093/dmj.2021.0280
27.
LaufsU, ParhoferKG, GinsbergHN, et al.Clinical review on triglycerides. Eur Heart J, 2020; 41(1):99c–109c; doi: 10.1093/eurheartj/ehz785
28.
BoT, GaoL, YaoZ, et al.Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab, 2024; 36(5):947–968; doi: 10.1016/j.cmet.2024.04.006
29.
LiuJ, LiuJ, LiP, et al.Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes mellitus, insulin resistance and blood lipid levels in Chinese population. Diabetes Res Clin Pract, 2008; 82(1):42–47; doi: 10.1016/j.diabres.2008.06.017
30.
SodiVL, BacigalupaZA, FerrerCM, et al.Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation. Oncogene, 2018; 37(7):924–934; doi: 10.1038/onc.2017.395
31.
WangY, ViscarraJ, KimSJ, et al.Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol, 2015; 16(11):678–689; doi: 10.1038/nrm4074
32.
FengJ, QiuS, ZhouS, et al.mTOR: A potential new target in nonalcoholic fatty liver disease. Int J Mol Sci, 2022; 23(16):9196; doi: 10.3390/ijms23169196
33.
SimmonsGEJr, PruittWM, PruittK. Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci, 2015; 16(1):950–965; doi: 10.3390/ijms16010950
34.
DemirS, NawrothPP, HerzigS, et al.Emerging targets in type 2 diabetes and diabetic complications. Adv Sci (Weinh), 2021; 8(18):e2100275; doi: 10.1002/advs.202100275
35.
UmpierrezG, KorytkowskiM. Diabetic emergencies—ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol, 2016; 12(4):222–232; doi: 10.1038/nrendo.2016.15
36.
TinajeroMG, MalikVS. An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol Metab Clin North Am, 2021; 50(3):337–355; doi: 10.1016/j.ecl.2021.05.013
37.
Pérez-BelmonteLM, Moreno-SantosI, Cabrera-BuenoF, et al.Expression of Sterol Regulatory Element-Binding Proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: Preliminary study. Int J Med Sci, 2017; 14(3):268–274; doi: 10.7150/ijms.17821
38.
CreweC, ZhuY, PaschoalVA, et al.SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. JCI Insight, 2019; 5(15):e129397; doi: 10.1172/jci.insight.129397
39.
LiN, LiX, DingY, et al.SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies. Biomedicines, 2023; 11(12):3280; doi: 10.3390/biomedicines11123280
40.
UeharaK, SantoleriD, WhitlockA, et al.Insulin regulation of hepatic lipid homeostasis. Compr Physiol, 2023; 13(3):4785–4809; doi: 10.1002/cphy.c220015
41.
SantoleriD, TitchenellPM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol, 2019; 7(2):447–456; doi: 10.1016/j.jcmgh.2018.10.016
42.
ZhouYJ, XuN, ZhangXC, et al.Chrysin improves glucose and lipid metabolism disorders by regulating the AMPK/PI3K/AKT signaling pathway in insulin-resistant HepG2 Cells and HFD/STZ-induced C57BL/6J mice. J Agric Food Chem, 2021; 69(20):5618–5627; doi: 10.1021/acs.jafc.1c01109
43.
LiG, ZhouF, ChenY, et al.Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c. Biomed Pharmacother, 2017; 89:536–543; doi: 10.1016/j.biopha.2017.02.024
44.
LeeG, JangH, KimYY, et al.SREBP1c-PAX4 axis mediates pancreatic β-cell compensatory responses upon metabolic stress. Diabetes, 2019; 68(1):81–94; doi: 10.2337/db18-0556
45.
EngelkingLJ, CantoriaMJ, XuY, et al.Developmental and extrahepatic physiological functions of SREBP pathway genes in mice. Semin Cell Dev Biol, 2018; 81:98–109; doi: 10.1016/j.semcdb.2017.07.011
46.
ChenG, WangT, UttarwarL, et al.SREBP-1 is a novel mediator of TGFβ1 signaling in mesangial cells. J Mol Cell Biol, 2014; 6(6):516–530; doi: 10.1093/jmcb/mju041
47.
MeyerM, SchwärzlerJ, JukicA, et al.Innate immunity and MASLD. Biomolecules, 2024; 14(4):476; doi: 10.3390/biom14040476
48.
ZouZ, LiuX, YuJ, et al.Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice. J Hepatol, 2024; 80(6):834–845; doi: 10.1016/j.jhep.2024.01.029
49.
CaballeroF, FernándezA, De LacyAM, et al.Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol, 2009; 50(4):789–796; doi: 10.1016/j.jhep.2008.12.016
50.
Fernández-AlvarezA, AlvarezMS, GonzalezR, et al.Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem, 2011; 286(24):21466–21477; doi: 10.1074/jbc.M110.209973
51.
KoenigAB, TanA, AbdelaalH, et al.Review article: Hepatic steatosis and its associations with acute and chronic liver diseases. Aliment Pharmacol Ther, 2024; 60(2):167–200; doi: 10.1111/apt.18059
52.
European Association for the Study of the Liver (EASL). Electronic address: ee, (EASD) EAftSoD, (EASO) EAftSoO, European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 2024; 81(3):492–542; doi: 10.1016/j.jhep.2024.04.031
53.
LimSH, LeeHS, HanHK, et al.Saikosaponin A and D inhibit adipogenesis via the AMPK and MAPK signaling pathways in 3T3-L1 adipocytes. Int J Mol Sci, 2021; 22(21):11409; doi: 10.3390/ijms222111409
54.
ChandrasekaranP, WeiskirchenR. The role of SCAP/SREBP as central regulators of lipid metabolism in hepatic steatosis. Int J Mol Sci, 2024; 25(2):1109; doi: 10.3390/ijms25021109
55.
LarionS, PadgettCA, ButcherJT, et al.The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. Am J Physiol Gastrointest Liver Physiol, 2022; 323(4):G387–G400; doi: 10.1152/ajpgi.00130.2022
56.
SaranAR, DaveS, ZarrinparA. Circadian rhythms in the pathogenesis and treatment of fatty liver disease. Gastroenterology, 2020; 158(7):1948–1966.e1; doi: 10.1053/j.gastro.2020.01.050
57.
ZhangY, PapazyanR, DamleM, et al.The hepatic circadian clock fine-tunes the lipogenic response to feeding through RORα/γ. Genes Dev, 2017; 31(12):1202–1211; doi: 10.1101/gad.302323.117
58.
YanR, CaoP, SongW, et al.A structure of human Scap bound to Insig-2 suggests how their interaction is regulated by sterols. Science, 2021; 371(6533):eabb2224; doi: 10.1126/science.abb2224
59.
LibbyP, RidkerPM, HanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011; 473(7347):317–325; doi: 10.1038/nature10146
60.
BułdakŁ. ŁCardiovascular Diseases—a focus on atherosclerosis, its prophylaxis, complications and recent advancements in therapies. Int J Mol Sci, 2022; 23(9):4695; doi: 10.3390/ijms23094695
61.
DevesaA, IbanezB, MalickWA, et al.Primary prevention of subclinical atherosclerosis in young adults: JACC review topic of the week. J Am Coll Cardiol, 2023; 82(22):2152–2162; doi: 10.1016/j.jacc.2023.09.817
62.
PengC, LeiP, LiX, et al.Down-regulated of SREBP-1 in circulating leukocyte is a risk factor for atherosclerosis: A case control study. Lipids Health Dis, 2019; 18(1):177; doi: 10.1186/s12944-019-1125-1
63.
Vargas-AlarconG, Gonzalez-PachecoH, Perez-MendezO, et al.SREBF1c and SREBF2 gene polymorphisms are associated with acute coronary syndrome and blood lipid levels in Mexican population. PLoS One, 2019; 14(9):e0222017; doi: 10.1371/journal.pone.0222017
64.
LibbyP. The changing landscape of atherosclerosis. Nature, 2021; 592(7855):524–533; doi: 10.1038/s41586-021-03392-8
65.
MundiS, MassaroM, ScodittiE, et al.Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res, 2018; 114(1):35–52; doi: 10.1093/cvr/cvx226
66.
ZhongS, LiL, ShenX, et al.An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med, 2019; 144:266–278; doi: 10.1016/j.freeradbiomed.2019.03.036
67.
YuanT, YangT, ChenH, et al.New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol, 2019; 20:247–260; doi: 10.1016/j.redox.2018.09.025
68.
ChistiakovDA, MelnichenkoAA, MyasoedovaVA, et al.Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl), 2017; 95(11):1153–1165; doi: 10.1007/s00109-017-1575-8
69.
MaengHJ, LeeGY, BaeJH, et al.Effect of fibroblast growth factor 21 on the development of atheromatous plaque and lipid metabolic profiles in an atherosclerosis-prone mouse model. Int J Mol Sci, 2020; 21(18):6836; doi: 10.3390/ijms21186836
70.
LinZ, PanX, WuF, et al.Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation, 2015; 131(21):1861–1871; doi: 10.1161/CIRCULATIONAHA.115.015308
71.
LeeW, AhnJH, ParkHH, et al.COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Signal Transduct Target Ther, 2020; 5(1):186; doi: 10.1038/s41392-020-00292-7
72.
LiY, WuS, ZhaoX, et al.Key events in cancer: Dysregulation of SREBPs. Front Pharmacol, 2023; 14:1130747; doi: 10.3389/fphar.2023.1130747
73.
ZhouQQ, XiaoHT, YangF, et al.Advancing targeted protein degradation for metabolic diseases therapy. Pharmacol Res, 2023; 188:106627; doi: 10.1016/j.phrs.2022.106627
74.
TangJJ, LiJG, QiW, et al.Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab, 2021; 33(1):222; doi: 10.1016/j.cmet.2020.11.013
75.
ShaoW, MachamerCE, EspenshadePJ. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res, 2016; 57(8):1564–1573; doi: 10.1194/jlr.M069583
76.
LeeSH, LeeJH, ImSS. The cellular function of SCAP in metabolic signaling. Exp Mol Med, 2020; 52(5):724–729; doi: 10.1038/s12276-020-0430-0
77.
LiuM, HansenPE, WangG, et al.Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules, 2015; 20(1):754–779; doi: 10.3390/molecules20010754
78.
AsanoL, WatanabeM, RyodenY, et al.Vitamin D metabolite, 25-hydroxyvitamin D, regulates lipid metabolism by inducing degradation of SREBP/SCAP. Cell Chem Biol, 2017; 24(2):207–217; doi: 10.1016/j.chembiol.2016.12.017
79.
KawagoeF, MendozaA, HayataY, et al.Discovery of a vitamin D receptor-silent vitamin d derivative that impairs sterol regulatory element-binding protein in vivo. J Med Chem, 2021; 64(9):5689–5709; doi: 10.1021/acs.jmedchem.0c02179
80.
ZhaoX, ZongH, AbdullaA, et al.Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes, 2014; 63(7):2464–2473; doi: 10.2337/db13-0835
81.
SoyalSM, NofzigerC, DossenaS, et al.Targeting SREBPs for treatment of the metabolic syndrome. Trends Pharmacol Sci, 2015; 36(6):406–416; doi: 10.1016/j.tips.2015.04.010
82.
JaroszewskiB, JelonekK, KasperczykJ. Drug delivery systems of betulin and its derivatives: An overview. Biomedicines, 2024; 12(6):1168; doi: 10.3390/biomedicines12061168
83.
AmiriS, DastghaibS, AhmadiM, et al.Betulin and its derivatives as novel compounds with different pharmacological effects. Biotechnol Adv, 2020; 38:107409; doi: 10.1016/j.biotechadv.2019.06.008
84.
GuiYZ, YanH, GaoF, et al.Betulin attenuates atherosclerosis in apoE(-/-) mice by up-regulating ABCA1 and ABCG1. Acta Pharmacol Sin, 2016; 37(10):1337–1348; doi: 10.1038/aps.2016.46
85.
BaiT, YangY, YaoYL, et al.Betulin alleviated ethanol-induced alcoholic liver injury via SIRT1/AMPK signaling pathway. Pharmacol Res, 2016; 105:1–12; doi: 10.1016/j.phrs.2015.12.022
86.
KamisukiS, ShirakawaT, KugimiyaA, et al.Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem, 2011; 54(13):4923–4927; doi: 10.1021/jm200304y
87.
KamisukiS, MaoQ, Abu-ElheigaL, et al.A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol, 2009; 16(8):882–892; doi: 10.1016/j.chembiol.2009.07.007
88.
AtteiaHH, AlFarisNA, AlshammariGM, et al.The hepatic antisteatosis effect of xanthohumol in high-fat diet-fed rats entails activation of AMPK as a possible protective mechanism. Foods, 2023; 12(23):4214; doi: 10.3390/foods12234214
89.
AggeletopoulouI, TsounisEP, TriantosC. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel mechanistic insights. Int J Mol Sci, 2024; 25(9):4901; doi: 10.3390/ijms25094901
90.
KawagoeF, MototaniS, MendozaA, et al.Structure-activity relationship studies on vitamin D-based selective SREBP/SCAP inhibitor KK-052. RSC Med Chem, 2023; 14(10):2030–2034; doi: 10.1039/d3md00352c
91.
PengZ, ChenL, WangM, et al.SREBP inhibitors: An updated patent review for 2008-present. Expert Opin Ther Pat, 2023; 33(10):669–680; doi: 10.1080/13543776.2023.2291393
92.
HendrixS, KingmaJ, OttenhoffR, et al.Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans. Nat Commun, 2023; 14(1):5181; doi: 10.1038/s41467-023-40943-1
93.
FerdousSE, FerrellJM. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Int J Mol Sci, 2024; 25(16):8731; doi: 10.3390/ijms25168731
94.
Villalobos-LabraR, SubiabreM, ToledoF, et al.Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol Aspects Med, 2019; 66:49–61; doi: 10.1016/j.mam.2018.11.001
95.
GaoG, ZhaoJ, DingJ, et al.Alisol B regulates AMPK/mTOR/SREBPs via directly targeting VDAC1 to alleviate hyperlipidemia. Phytomedicine, 2024; 128:155313; doi: 10.1016/j.phymed.2023.155313
96.
NakagawaY, OikawaF, MizunoS, et al.Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system. Sci Rep, 2016; 6:27857; doi: 10.1038/srep27857
97.
SkubicC, DrakulićŽ, RozmanD. Personalized therapy when tackling nonalcoholic fatty liver disease: A focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol, 2018; 14(8):831–841; doi: 10.1080/17425255.2018.1492552
